Clinical Trial Update: To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Planned Phase 1/2 safety study of SG2918 in patients with relapsed or refractory multiple myeloma, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• SG2918 (SG2918)

Snippet

Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING